The Scottish Medicines Consortium (SMC) have announced that sotatercept, the ‘first in class’ PAH treatment, will not be commissioned for use by NHS Scotland at this stage.
9 February 2026
The UK’s specialist PH service is the envy of the world, and the latest National Audit of Pulmonary Hypertension has once again confirmed that it delivers high standards of care for patients.
19 January 2026
It has been announced today, 27th August, that at this stage the new PAH treatment sotatercept will not be commissioned for use by NHS England.
27 August 2025
The new PAH treatment sotatercept has now been approved for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
2 January 2025
Following a rigorous assessment, our information resources have been re-certified with a Patient Information Forum (PIF) quality mark for the fourth year running.
19 July 2024
The PAH therapy sotatercept is the first drug to target the root cause of the disease, and trials have produced promising results. But as 2023 draws to a close, are we any closer to it being made available for patients?
4 December 2023
